Navigation Links
XTL Biopharmaceuticals Implements Restructuring Plan
Date:12/8/2008

VALLEY COTTAGE, N.Y., Dec. 8 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announced today that it is restructuring its operations following the failure of the Bicifadine Phase 2b clinical trial. The company is terminating the employment of 9 employees, representing 75% of its workforce. The remaining employees will be responsible for seeking potential assets or a company to merge into XTL, or for assisting in the liquidation and/or disposition of XTL's assets.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future business prospects, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. It is possible that we will not be able to find a buyer for the assets or a merger partner. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.xtlbio.com . The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
8. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
11. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... The science of light and how ... more than 200 primary students in a traveling program ... of Otago Physics Department and funded by an ... of the university’s OSA/SPIE Student Chapter visited six primary ... children from small, rural schools hands-on lessons in optics ...
(Date:11/21/2014)... Los Angeles, CA (PRWEB) November 20, 2014 ... “A Short Walk to the Other Side” ... was an “Award-Winning Finalist in the “Fiction: Short Story” ... . , Jeffrey Keen, President and CEO of USA ... entries from mainstream and independent publishers, including Simon & ...
(Date:11/21/2014)... 2014 The report, "Synthetic ... Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, Gene ... Biomaterials, Bioremediation) - Global Forecast to 2018", ... threats, opportunities, and challenges. , Browse 99 ... through 185 pages and in-depth TOC of ...
(Date:11/21/2014)... 2014 BlueInGreen, LLC ( BlueInGreen® ... (Pinnacle), and PCI, Inc., leading suppliers of ozone ... been selected to provide a new state-of-the-art ozone ... R. Noland Wastewater Treatment. The new ozone ... gas dissolution technology, Pinnacle Ozone’s industry leading ...
Breaking Biology Technology:Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4
... LAIYANG, China, Sept. 2 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals, Inc. (OTC ... with its principal operations in the People,s,Republic of China, ... will,present at the upcoming Rodman & Renshaw Annual Global ... New York Palace Hotel in New York City. , ...
... , , SOUTH SAN ... announced the first commercial sales of a new ... treatment of New York Heart Association Class III and IV ... same dose of Ventavis in half the volume, which is ...
... KALAMAZOO, Mich., Sept. 1 Stryker Corporation (NYSE: ... , Lonny J. Carpenter, currently Group President, ... President, Global Quality and Operations, reporting to Stephen P. MacMillan, ... Carpenter will be responsible for setting and executing company-wide quality, ...
Cached Biology Technology:Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference 2Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference 3Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States 2Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States 3Stryker Announces Organizational Changes 2
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
(Date:11/15/2014)... 13, 2014  While we may still be a few ... in "Star Trek" to gain instant access to all that ... with smartphones and tablets for monitoring and measuring our health ... This may seem a tad Orwellian to some, but a ... of these technological opportunities into their healthcare regime. ...
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... Scientists are calling for more research on the possibility ... renowned for their apparent ability to prevent cancer ... individuals. Their recommendation follows a study in which two ... to aggravate kidney cancer in severely diabetic laboratory rats. ...
... the abstracts to be presented at the EORTC-NCI-AACR [1] Symposium on ... before the meeting at 00.01 hrs CET on Friday 29 October. ... are free to report on the online abstracts from the time ... bear in mind that all the abstracts had to be submitted ...
... , Blacksburg, Va. -- The USDA,s National Institute of ... the College of Agriculture and Life Sciences at Virginia ... grape and wine quality in the eastern United States. ... project director, the five-year project seeks to create, refine, ...
Cached Biology News:Abstracts for the EORTC-NCI-AACR Symposium in Berlin go up online on Friday, Oct. 29 2USDA awards Virginia Tech $3.8 million to stimulate eastern US wine industry 2
... N. Fernandez and G. Butcher (1998). • ... of much research in the immunology area. ... of MHC proteins and in their function ... now faced with the prospect of tackling ...
delta-like 1 homolog (Drosophila)...
ELISpot kit for human Granzyme B. Kits contain PVDF plates, capture & detection antibodies, streptavidin-ALP, BSA, Skimmed dry milk, BCIP/NTB substrate, and wash buffer...
SHEEP ANTI ECHIS OCCELATUS (VENOM)...
Biology Products: